

1 Liver Shape Analysis using Statistical 2 Parametric Maps at Population Scale

3 Marjola Thanaj¹, Nicolas Bastay¹, Madeleine Cule², Elena P Sorokin², Brandon Witcher¹,
4 Jimmy D Bell¹, E Louise Thomas¹

5 1 Research Centre for Optimal Health, School of Life Sciences, University of Westminster,
6 London, United Kingdom,

7 2 Calico Life Sciences LLC, South San Francisco, CA, United States

8

9 Corresponding Author: m.thanaj@westminster.ac.uk

10

11 **Abstract**

12 **Background:** Morphometric image analysis enables the quantification of differences in the
13 shape and size of organs between individuals.

14 **Methods:** Here we have applied morphometric methods to the study of the liver by
15 constructing surface meshes from liver segmentations from abdominal MRI images in
16 33,434 participants in the UK Biobank. Based on these three-dimensional mesh vertices, we
17 evaluated local shape variations and modelled their association with anthropometric,
18 phenotypic and clinical conditions, including liver disease and type-2 diabetes.

19 **Results:** We found that age, body mass index, hepatic fat and iron content, as well as,
20 health traits were significantly associated with regional liver shape and size. Interaction
21 models in groups with specific clinical conditions showed that the presence of type-2
22 diabetes accelerates age-related changes in the liver, while presence of liver fat further
23 increased shape variations in both type-2 diabetes and liver disease.

24 **Conclusions:** The results suggest that this novel approach may greatly benefit studies
25 aiming at better categorisation of pathologies associated with acute and chronic clinical
26 conditions.

27

28 **Key Words:** Magnetic Resonance Imaging, Liver Volume, Surface mesh, Image Analysis,
29 3D mesh-derived phenotype, Statistical Parametric Maps, Type-2 Diabetes.

30

31 **Abbreviations:** T2D: Type 2 Diabetes; BMI: Body mass index; WHR: waist-to-hip ratio;
32 AST:ALT: ratio of aspartate aminotransferase to alanine aminotransferase; FIB-4: Fibrosis-4
33 index; Liver PDFF: Liver percentage density fat fraction; MUR : Mass univariate regression;
34 TFCE: Threshold-free cluster enhancement; SPMs: Statistical parametric maps; S2S:
35 Surface-to-surface.

36

37 **Introduction**

38

39 Despite improvements in global health [1], incidence of liver disease continues to
40 rise, with deaths due to hepatic conditions increasing by 400% since the 1970s (British Liver
41 Trust - <https://britishlivertrust.org.uk/>), making it the leading cause of death in those aged 35-
42 49 years in the UK (ONS 2019 - <https://www.ons.gov.uk/>). Significant progress has been
43 made in recent years in the use of non-invasive imaging methods to measure the
44 pathological changes that are features of increasingly common liver conditions. This
45 includes non-alcoholic fatty liver disease (NAFLD) [2, 3], fibro-inflammation [4, 5] and fibrosis
46 [6]. The prevalence of these conditions, associated with obesity, insulin resistance and type-
47 2 diabetes (T2D), are likely only to increase further given the current obesogenic
48 environment. New approaches are needed to differentiate between those with mild disease,
49 compared with those at risk of more significant conditions (cirrhosis/end stage liver disease),
50 and particularly those who may experience accelerated disease processes [7]. One potential
51 approach to address these issues is the implementation of novel morphometric methods to

52 gain a deeper understanding of the processes underpinning the development and
53 progression of many clinical conditions [8]. For instance, investigating whether changes
54 beyond simple volume or fat measurements, such as liver shape, are associated with
55 particular environmental risk factors, or whether they can be differentially related to the
56 aetiology of a particular condition. These methods may potentially provide insight into
57 different mechanisms of disease development and enable optimised treatment strategies to
58 be developed.

59

60 Automated segmentation of the liver to produce image-derived phenotypes (IDPs)
61 such as volume or fat deposition measurements are becoming more commonplace at scale
62 as deep learning methods gain traction [9]. While these methods enhance our understanding
63 of the liver at a population level, they are limited when it comes to providing additional
64 knowledge regarding morphological, functional and regional variation in response to a
65 particular condition.

66

67 Mapping organ segmentations to a standardised three-dimensional (3D) surface
68 mesh, enables many thousands of measurements relating to variation in organ shape to be
69 performed using statistical parametric maps (SPMs). A similar widely applied technique,
70 which transforms the 3D surface mesh measurements into a smaller number of principal
71 components, known as shape parameters, has been used to characterise variations in organ
72 shape across a population. These approaches have been successfully applied in
73 neuroimaging [10, 11], abdominal computer tomography (CT) images [12, 13], and cardiac
74 imaging [14, 15] and they have shown to be useful in identifying genetic interactions with
75 cardiac pathology [16] and brain ageing [17]. However, they have been less frequently
76 applied to abdominal organs, where morphological changes are known to take place in a
77 variety of clinical conditions [18, 19].

78

79 In the current study we have applied SPM methods to determine morphological
80 variations in the liver and their potential association with anthropometric traits and clinical
81 conditions.

82

83 **Methods**

84

85 *Data*

86 The UK Biobank [20] is a population-based study in which 500,000 participants aged
87 40 to 70 years were recruited for deep phenotypic profiling. There is also a currently ongoing
88 imaging sub-study, in which 100,000 of the participants have been recruited to undergo an
89 imaging protocol including MRI of the brain, the heart, and the abdominal region. The
90 abdominal scans include a neck-to-knee Dixon 3D acquisition that can be used to derive
91 volumes of adipose tissue, skeletal muscle and abdominal organs. Full details regarding the
92 UK Biobank abdominal acquisition protocol have previously been reported [21]. We
93 processed and segmented the data using our automated methods [9]. In this study on liver
94 morphology, we included 41,800 participants with Dixon MRI data acquired at the imaging
95 visit, between 2014 and 2020 with data comprising imaging, health-related diagnoses and
96 biological measurements.

97

98 Participants with missing clinical, anthropometric or biochemical data, as well as
99 those with Dixon MRI datasets that did not have full anatomical coverage were excluded
100 from the study. We then performed quality control by visually inspecting potential outliers in
101 the 3D liver mesh-derived phenotype (i.e. extremely high values). Overall, from the initial
102 41,800 participants, 33,434 participants were included in the final analysis (20% of data
103 excluded).

104

105 Fully anonymized participant data was obtained through UK Biobank Access
106 Application number 44584. The UK Biobank has approval from the North West Multi-Centre

107 Research Ethics Committee (REC reference: 11/NW/0382) written informed consent was
108 obtained from all participants prior to inclusion in the UK Biobank.

109

110 *Phenotype Definitions*

111 Anthropometric measurements including age, body mass index (BMI), waist and hip
112 circumferences were taken at the UK Biobank imaging visit and ethnicity was defined based
113 on the continental genetic ancestry (<https://pan.ukbb.broadinstitute.org>). AST:ALT ratio,
114 defined as the ratio of aspartate aminotransferase (AST) to alanine aminotransferase (ALT),
115 commonly used to indicate presence of more advanced liver disease including fibrosis and
116 cirrhosis [22, 23] was calculated from the biological samples taken at the initial assessment
117 visit. The fibrosis-4 index (FIB-4), also designed to identify more advanced stages of liver
118 disease and fibrosis in particular, was calculated as previously described [24] using age,
119 AST, ALT and platelet count taken from the initial assessment visit. Diagnosis of liver
120 disease and T2D was obtained from UK Biobank hospital records and self-reported
121 information (see Disease Categories in supporting information). Due to the relatively limited
122 number of scanned participants within the UKBB diagnosed with specific liver diseases, a
123 broad umbrella definition of liver disease was implemented which included, alcoholic liver
124 disease, fibrosis, cirrhosis, and chronic hepatitis.

125

126 *Study Design*

127 *Template Definition*

128 Deformation of an image to a standard organ template is a key part of MRI organ
129 shape assessment. Given the potential variation in morphology, it is important to identify a
130 suitable population sample size for constructing a template image [25]. To assess the impact
131 of population size on template construction, we constructed three distinct templates using
132 liver segmentations from a gender-balanced European ancestry cohort of 20, 100 and 200
133 participants with BMI < 25 kg/m² and low liver fat (<5%). The characteristics for each template
134 population are provided in S1 Table. To test the 3 templates, we selected 500 participants,

135 derived from the full cohort, with European genetic ancestry, aged between 46 and 62 years
136 old, without any disease reported or diagnosed here [26] (S2 Table). We then registered the
137 three liver templates to the 500-participant cohort and investigated the associations between
138 the 3D mesh-derived phenotype and the anthropometric covariates across the three
139 templates.

140

141 *Association between mesh-derived phenotypes, IDPs and Disease*

142 To assess the associations between the 3D mesh-derived phenotype, the
143 anthropometric covariates and liver IDPs (volume, fat, iron), we first analysed the liver MRI
144 data from the entire UK Biobank imaging cohort. The cohort of 33,434 participants was
145 97.6% European, 48.7% male and aged between 44 and 82 years old (S3 Table). To
146 determine the potential association between disease and liver shape, we first selected
147 diseases that are known from previous studies to impact liver health, and are associated
148 with changes in liver fat accumulation or volume [9]. These included 449 participants with
149 liver disease (207F/242M; 48-81 years old; BMI 18.6-43.8 kg/m²) and 1,780 participants with
150 T2D (67% males; 46-82 years old; BMI 18.3-50.1 kg/m²) (S4 Table).

151

152 *Image Registration and Mesh Construction*

153 The process for template construction of the liver has been previously described [27].
154 Here, we constructed three distinct templates using liver segmentations from 20, 100 and
155 200 subject-specific volumes in order to evaluate the impact of cohort size on template
156 construction. It also allows us to test if cohort size influenced the statistical associations in
157 our mesh-based analysis. We constructed surface meshes from each template using the
158 marching cubes algorithm and smoothed using a Laplacian filter [28]. The template
159 construction was performed using ANTs software (<https://picsl.upenn.edu/software/ants>) with
160 mutual information as the similarity metric, the B-spline non-rigid transformation model and
161 default parameters otherwise.

162

163 Surface meshes were first constructed from each subject's segmentations using
164 marching cubes algorithm and smoothed using a Laplacian filter. Rigid registration was then
165 used to remove the position and orientation difference between all subject-specific surfaces
166 and template surfaces and an affine transformation with nearest neighbour interpolation was
167 computed between template and subject segmentations. The resulting affine transformations
168 were used to warp the template to the subject's space. The template segmentation is then
169 mapped into each subject segmentation by computing a non-rigid transformation modelled
170 by a free-form deformation, based on B-Splines, with label consistency as the similarity
171 metric between the subject and template liver segmentations [29]. To enable subject
172 comparison with vertex-to-vertex correspondence, the template mesh is then warped to each
173 subject mesh using the deformation fields obtained from the non-rigid registration. Hence, all
174 surface meshes are parameterised with the same number of vertices (approximately
175 18,000). This ensures each vertex is anatomically accurate and consistent across all
176 subjects while preserving the size and shape information for subsequent analysis [28].

177

178 To determine the regional outward or inward adaptations in the liver surface in
179 comparison to an average liver shape, the surface-to-surface (S2S) distance, a 3D mesh-
180 derived phenotype for each subject was measured. This was achieved by computing the
181 signed distance between each vertex in the template mesh and each corresponding vertex
182 in the subjects' mesh. This indicates positive distances for outward expansion in the
183 subject's vertices compared to template vertices and negative distances for inward
184 shrinkage in the subject's vertices. Finally, after performing the aforementioned manual
185 quality control on the S2S values, all values were between -48.3 to 70.5 mm. All the steps
186 above were performed using the Image Registration Toolkit (IRTK)
187 (<https://biomedica.doc.ic.ac.uk/software/irtk>).

188

189 *Mass Univariate Regression*

190 Associations between the S2S values and anthropometric variables were modelled
191 using a linear regression framework. We applied threshold-free cluster enhancement (TFCE)
192 [30] and permutation testing to assess the associations between S2S distances and
193 anthropometric covariates, as well as liver fat and iron content. These were adjusted for
194 relevant covariates with correction to control the false discovery rate (FDR), as previously
195 described [27]. Specifically, we performed mass univariate regression (MUR) analysis using
196 a refined version of the R package *mutools 3D* [31] and adjusted for multiple comparisons by
197 applying the FDR procedure [32] to all the TFCE p-values derived from each vertex and
198 each model using 1,000 permutations. The estimated regression coefficients $\hat{\beta}$ for each of
199 the relevant covariates and their related p-values were then displayed at each vertex in the
200 mesh on the whole 3D liver anatomy, providing the spatially-distributed associations. The
201 MUR model for deriving associations between clinical parameters and a 3D phenotype is
202 outlined in Supplementary Fig. S1.

203

204 To determine which factors influence the design and performance of the liver
205 template, we used a regression model to address: (1) how many participants are required to
206 construct a representative liver template, (2) whether the template population size affected
207 the associations between the S2S and the anthropometric covariates, (3) which factors have
208 an impact on regional S2S distances and (4) how are the changes in S2S distances linked to
209 liver disease and T2D.

210

211 We constructed three models adjusting for additional covariates. **Model 1** was
212 adjusted for age, gender, ethnicity, body mass index (BMI) and waist-to-hip ratio (WHR),
213 liver fat (referred to as proton density fat fraction (PDFF)) and liver iron concentration with
214 correction to control the FDR. To investigate the morphological changes related to liver
215 function **Model 2** had all the covariates from model 1 plus AST:ALT, FIB-4 index and
216 disease conditions. We further adjusted with interaction terms between age and disease
217 status and between liver fat and disease. In order to test whether there is a circadian effect

218 in the liver morphology, **Model 3** included all the covariates from model 2 plus time of the
219 day for the MRI scan, discretised into hours of the day.

220

221 **Results**

222

223 *Template Consistency*

224 We constructed 3 separate template meshes using gender-balanced cohorts of 20,
225 100 and 200 participants and computed the distances between each template mesh for each
226 subpopulation (Supplementary Fig. S2). The results showed that cohort size had little impact
227 on the shape of the template, with differences less than 8mm, especially for the templates
228 constructed using 100 participants compared with the 200-participant template.

229

230 We then investigated for each template the associations between S2S distances and
231 anthropometric variables, adjusting for the covariates in Model 1. Here we only looked at the
232 associations between BMI and WHR with S2S distances, as only these variables showed
233 statistically significant associations. The 3D SPMs, with the TFCE corrected p-values,
234 between BMI and S2S distance on the previously selected 500-participants cohort showed
235 that the distribution of the corrected p-values were consistent across all three different
236 templates (Supplementary Fig. S3). As shown in Table 1, there was no apparent difference
237 in the areas of association between BMI and WHR with S2S distances across the three
238 templates.

239

Significance area	20-participant template		100-participant template		200-participant template	
	BMI	WHR	BMI	WHR	BMI	WHR

Total	58.08%	14.48%	55.20%	18.28%	56.73%	12.12%
$\hat{\beta} < 0$	2.74%	4.79%	3.28%	7.42%	2.66%	4.67%
$\hat{\beta} > 0$	55.34%	9.69%	51.92%	10.85%	54.07%	7.46%

240 **Table 1.** Significance areas from the association between BMI and WHR with S2S distances
 241 on a 500-participants cohort, in the MUR model using a template with 20, 100 and 200
 242 participants. The significance area is the percentage of vertices on the liver mesh where the
 243 regression coefficients are statistically significant ($p < 0.05$) after adjustment for multiple
 244 comparisons. The total area has been split into areas of negative ($\hat{\beta} < 0$) and positive ($\hat{\beta} >$
 245 0) associations.

246

247 In order to test template consistency on a disease population, all three templates
 248 were registered on a cohort of 449 participants with liver disease and the 3D S2S phenotype
 249 computed between template and participants' surface. We then modelled the associations
 250 between the S2S distances and anthropometric variables adjusting for the covariates in
 251 model 1. The TFCE corrected p-value maps on the cohort with liver disease were consistent
 252 across the three templates, with little difference in the significance area for the association
 253 between BMI and S2S distances (97.58% using the 20-participant template, 97.46% using
 254 the 100-participant template and 96.43% using the 200-participant template) (S4 Fig and
 255 Table 2).

256

Significance area	20-participant template		100-participant template		200-participant template	
	BMI	WHR	BMI	WHR	BMI	WHR

Total	97.58%	91.02%	97.46%	90.31%	96.43%	90.98%
$\hat{\beta} < 0$	0.01%	0.01%	0%	0%	0%	0%
$\hat{\beta} > 0$	97.57%	91.01%	97.46%	90.31%	96.43%	90.98%

257 **Table 2.** Significance areas from the association between BMI and WHR with S2S distances
 258 on a cohort with liver disease (N=449), in the MUR model using a template with 20, 100 and
 259 200 participants. The significance area is the percentage of vertices on the liver mesh where
 260 the regression coefficients are statistically significant ($p < 0.05$) after adjustment for multiple
 261 comparisons. The total area has been split into areas of negative ($\hat{\beta} < 0$) and positive ($\hat{\beta} >$
 262 0) associations.

263

264 *Associations with Anthropometric Characteristics, Liver IDPs and Disease*

265 As the liver template was relatively insensitive to the number of participants included,
 266 we performed all subsequent analyses using the 200-participant template. We proceeded to
 267 register the template on the full cohort (N=33,434), computing S2S distances between the
 268 template and surface of each individual liver mesh and performed MUR analysis adjusting
 269 for the covariates in Model 2.

270

271 A summary of the model for the whole cohort, representing the regression
 272 coefficients and the significance areas on the liver, is provided in Table 3 and
 273 Supplementary Fig. S5. The SPMs that represent associations between S2S distances and
 274 the anthropometric measurements and liver IDPs with units in standard deviations for each
 275 covariate, are shown in Fig. 1.

276


277 Lower S2S distances were associated with greater age over 96.63% of the liver, with
 278 a median change of -0.11 mm/year, while BMI and WHR had statistically significant positive
 279 associations with S2S distances, covering 97.82% and 58.11% of the liver, respectively. The

280 AST:ALT ratio showed mostly statistically significant positive association with S2S distances
281 in the anterior part of the left lobe and the posterior part of the right lobe, with a median
282 difference of 0.30 mm (significance area = 48.05%). FIB-4 index on the other hand showed a
283 median S2S distance of -0.22 mm (significance area = 82.62%). Liver PDFF was positively
284 associated with S2S distances, showing median outward shape variations of 0.26 mm/%,
285 whereas liver iron concentration was associated with S2S distances of -0.59 mm/(mg/g) in
286 the anterior part of the right lobe and the posterior part of the left lobe and a median 0.34
287 mm/(mg/g) in the anterior part of the left and caudate lobe. Additionally, we included MRI
288 scan time as an additional covariate in the model since liver size is known to vary during the
289 day [9], but this had no apparent effect on any of the associations (Supplementary Table S5,
290 Supplementary Fig. S6).

291

292 A diagnosis of liver disease was associated with a median S2S of -2.13 mm when
293 compared to the controls (significance area = 21.90%) in the anterior part of the right lobe as
294 well as at the posterior part of left and right lobe and a median of 1.95 mm (significance area
295 = 25.14%) in the anterior part of the left lobe. T2D was positively associated with S2S
296 distances, with a median of 2.42 mm for participants with T2D covering a significance area
297 of 86.40% of the liver. The time of day at which the MRI scan was conducted had no effect
298 on the associations between S2S and T2D, although we observed a reduction in the
299 significance area for the associations between S2S and liver disease (significance area =
300 28.34%, Supplementary Table S5, Supplementary Fig. S6).

301



302

303 **Figure 1.** Three-dimensional statistical parametric maps (SPMs) of liver morphology, two

304 projections are shown for each SPM providing anterior (left) and posterior (right) views of the

305 liver. The SPMs show the local strength of association for each covariate in model 2 with

306 S2S distances on the full cohort (N=33,434). Yellow contour lines indicate the boundary
 307 between statistically significant regions ($p < 0.05$) after correction for multiple testing, with
 308 positive associations in red and negative associations in blue. Standardised regression
 309 coefficients are shown with units in standard deviations for each covariate. BMI: body mass
 310 index, WHR: waist-to-hip ratio, AST:ALT: aspartate aminotransferase/alanine
 311 aminotransferase ratio, FIB-4: Fibrosis-4 score, Liver PDFF: Liver percentage density fat
 312 fraction, T2D: type-2 diabetes.
 313

	$\hat{\beta} < 0$		$\hat{\beta} > 0$		Total
	Beta coefficients	Significance area	Beta coefficients	Significance area	Significance area
Age (yrs.)	-0.11 (0.06)	96.63%	0.02 (0.04)	1.46%	98.10%
BMI (kg/m^2)	-0.08 (0.07)	1.61%	0.30 (0.22)	97.82%	99.43%
WHR	-3.88 (4.02)	33.99%	3.87 (3.65)	58.11%	92.10%
AST:ALT	-0.32 (0.32)	35.17%	0.30 (0.29)	48.05%	83.22%
FIB-4	-0.22 (0.17)	82.62%	0.23 (0.13)	2.09%	84.70%
Liver PDFF (%)	-0.03 (0.02)	0.17%	0.26 (0.10)	99.65%	99.82%
Liver Iron (mg/g)	-0.59 (0.74)	58.00%	0.34 (0.32)	24.99%	82.98%
Liver disease	-2.13 (2.95)	21.90%	1.95 (2.43)	25.14%	47.05%
T2D	-0.61 (0.77)	5.35%	2.42 (1.94)	86.40%	91.76%


Age * Liver disease	ns	ns	ns	ns	ns
Liver PDFF * Liver disease	-0.09 (0.01)	0.09%	0.09 (0.03)	12.59%	12.68%
Age * T2D	-0.03 (0.02)	71.23%	0	0%	71.23%
Liver PDFF * T2D	-0.06 (0.04)	6.24%	0.10 (0.08)	82.84%	89.08%

314 **Table 3.** Significance areas for covariates in the MUR model between the anthropometric
315 covariates and liver IDPs (N=33,434) in model 2. The total area has been split into areas of
316 positive and negative associations. The regression coefficients are presented as median
317 (interquartile range - IQR) and the significance areas as a percentage (%) of the vertices.
318 Where BMI: body mass index, WHR: waist-to-hip ratio, AST:ALT: aspartate
319 aminotransferase/alanine aminotransferase ratio, FIB-4: Fibrosis-4 score, Liver PDFF: Liver
320 percentage density fat fraction, T2D: type-2 diabetes, ns: not significant.

321

322 We undertook further analysis to determine whether there was an interaction
323 between clinicalstate and factors such as age and liver PDFF adjusted for all covariates in
324 Model 2. Our results varied according to the disease of interest. While there were no
325 significant associations for the interaction between age and liver clinical condition, we found
326 a median association of -0.14mm/year in T2D participants, compared with -0.11mm/year in
327 non-T2D participants, over a similar anatomical region. The interaction term between age
328 and T2D in this model was significantly different from zero, with a significance area =
329 71.23% (Table 3 and Fig. 1). The association between age and S2S distances in participants
330 with and without T2D are directly compared in Fig. 2, where participants diagnosed with T2D
331 display accelerated decreases in the anterior part of the left and right lobe as well as at the
332 posterior part of left and right lobe of the liver.

333




334

335 **Figure 2.** Three-dimensional statistical parametric maps (SPMs) of liver morphology,
336 projections are anterior (left) and posterior (right). The SPMs show the local rate of change
337 as a function of age for S2S distances in participants (i) without T2D versus those (ii) with
338 T2D on the full cohort (N=33,434). Positive associations are in red and negative associations
339 in blue. Standardised regression coefficients are shown with units in standard deviations.

340

341 The presence of liver PDFF in participants with liver disease resulted in an additional
342 median variation of 0.09 mm/% over an area 12.59% of the liver, in addition to the median
343 variation of 0.26 mm/% associated with the main effect of liver PDFF (Table 3 and Fig. 1).
344 Interestingly this effect was no longer significant after including scan-time as an additional
345 covariate in the model (Supplementary Table S5, Supplementary Fig. S6). A change of
346 similar magnitude, over a much larger proportion of the liver was observed for the interaction
347 between liver PDFF and T2D (Table 3 and Fig. 1). Here we observed an accelerated
348 increase in S2S distances with a median change of 0.10 mm/%, over the majority of the liver
349 surface area (significance area = 82.84%), in addition to the median increase of 0.26 mm/%

350 for the main effect of liver PDFF. The rates of change in S2S distances due to changes in
351 liver PDFF for participants with liver disease only, with T2D only and those without either
352 disease are directly compared in Fig. 3. The local variations associated with liver PDFF
353 fluctuates significantly with disease diagnosis. Participants diagnosed with liver disease (Fig.
354 3ii) display accelerated increases in S2S distances in the anterior and posterior parts of the
355 right lobe with increasing liver PDFF, with slight decreases in the rate of change in both the
356 anterior and posterior left lobe when compared to participants without either liver disease or
357 T2D. Participants with T2D (Fig. 3iii) display accelerated increases in S2S distances in the
358 anterior and posterior right lobe and the posterior left lobe when compared to participants
359 without T2D, and display substantial decreases in the rate of change in S2S distances in the
360 anterior left lobe when compared to participants who have been diagnosed with liver disease
361 but not T2D or participants who have not been diagnosed with either liver disease or T2D.



363 **Figure 3.** Three-dimensional statistical parametric maps (SPMs) of liver morphology,
364 projections are anterior (left) and posterior (right). The SPMs show the rate of change as a
365 function of liver PDFF for S2S distances in participants (i) without liver disease or T2D, (ii)
366 with liver disease only and (iii) with T2D only on the full cohort (N=33,434). Positive
367 associations are in red and negative associations in blue. Standardised regression
368 coefficients are shown with units in standard deviations.

369

370 **Discussion**

371

372 In this study, we mapped local shape variations across the liver and determined how
373 these changes were associated with anthropometric, phenotypic and health traits. To
374 achieve this we constructed surface meshes from liver segmentations of 33,434 participants
375 from the UK Biobank. Previous studies using similar SPMs have suggested that this is a
376 useful technique in neuroimaging [10] and cardiac imaging [14], enabling the associations
377 between phenotypic and genetic variation in specific anatomical regions to be mapped [16].

378

379 First, we constructed a representative liver template, and showed that a 200-
380 participant template was sufficient to represent the broader cohort. Indeed, the number of
381 participants included in the template construction did not impact the power of the statistical
382 analysis across a 500-participant test cohort, or a second cohort of 479 participants with liver
383 disease. This is in line with previous studies that found a cohort with 100 participants was
384 sufficient to construct a representative cardiac template to investigate the shape of the left
385 ventricle [28].

386

387 Liver size has been explored extensively using a variety of approaches from autopsy
388 measurements [33], CT [34], ultrasound [35], and MRI [19], as well as regression-based
389 algorithms designed to predict liver size based on body surface area [36]. Given accurate
390 assessment of liver volume is essential for many aspects of hepatic surgery and determining

391 disease progression [37], suitable methods are needed. However, until recently, the manual
392 annotation required to make true volumetric measurements of the liver from CT and MRI
393 images has been extremely time consuming. Imaging studies tended to rely on more easily
394 measured metrics, such as liver span or diameter [38, 39], or calculation of volume indices
395 from the measurement of multiple diameters [40]. Consequently, these approaches limit in
396 depth morphometric assessment and only provide information associated with overall
397 changes to liver size or volume. The SPM method implemented in the current study
398 demonstrates significant regional variations in liver shape associated with anthropometric
399 variables and disease status, including simultaneous inwards and outwards adaptations.
400 These novel phenotypic variables may be useful in longitudinal population studies, as well as
401 determining trajectories of progression in aggressive clinical conditions, including monitoring
402 liver cirrhosis and hepatic oncology. It may also be a powerful adjunct tool in clinical trials
403 aimed at reversing liver conditions such as cirrhosis.

404

405 While studies of liver volume have generally focussed on patient populations, there is
406 increasing interest in understanding how hepatic volume and form is influenced by age,
407 anthropometry and metabolic markers in the wider population [9, 40]. Despite this, few
408 studies employ methods that enable precise measurements of these parameters, particularly
409 with regard to regional variation in liver shape and size. In the present study we observed
410 that decline in the liver S2S distances were associated with increasing age. This is in
411 agreement with previous observations, by ourselves and others, that overall liver volume
412 decreases with age [9, 35, 41]. However, there are some ultrasound reports suggesting liver
413 size increases with age [38]. This discrepancy may relate to variations in methodology since
414 ultrasound measurements of liver diameter may not reflect overall changes in liver volume.
415 This clearly reinforces the importance of absolute volumetric measurements, which, when
416 combined with statistical parametric mapping, enables simultaneous extraction of global and
417 local changes.

418

419 We found a strong and distinct regionality in liver morphometry which was associated
420 with anthropometric traits, liver PDFF and disease. Higher liver PDFF was significantly
421 associated with positive S2S distances, suggesting that hepatic fat is associated with both
422 liver size and shape, with some clear regional variations. We also found that higher BMI and
423 WHR were strongly associated with positive S2S distance, in line with others who have
424 reported a positive correlation between liver size and anthropometric variables [39, 40]. We
425 also explored whether the time of day the participants were scanned was associated with
426 S2S distances, given we have previously shown this to be associated with fluctuations in
427 liver volume [9]. However, we did not find a measurable effect.

428

429 We also investigated whether conditions with known involvement of hepatic function
430 had discernible effects on our S2S measurements. For this we selected T2D, commonly
431 associated with increased deposition of liver PDFF, and subjects with known liver conditions,
432 which we expected to be associated with a more adverse phenotype. We found that T2D
433 was associated with outward shape variations in the liver after adjusting for PDFF,
434 suggesting that T2D affects liver morphology. It is well recognised that T2D is associated
435 with a range of liver conditions, with the prevalence of NAFLD in patients with T2D reported
436 to be 55% and NASH 37.3% [42], substantially higher than the proportion of individuals in
437 the general population with NAFLD (19.9%) [3] or NASH (2.2%) [43]. Given the clinical
438 heterogeneity of our current T2D cohort, in terms of time of diagnosis and medication, as
439 well as the possibility of collider bias or reverse confounding, it is impossible to identify
440 causal mechanisms for the observed variation in S2S distances. Interestingly when we
441 considered the interaction between age and disease, we found no statistically significant
442 interaction for liver disease, but there was a significant interaction between age and the
443 presence of T2D. We also considered whether the interaction between disease and the
444 presence of liver PDFF was associated with S2S distances. Moreover, the variations
445 covered a larger proportion of the liver in T2D compared with liver disease. This may
446 suggest that the hepatic tissue in T2D retains its overall relative plasticity (i.e. less fibrotic-

447 cirrhotic tissue), while in liver disease there may be regions that have reduced capacity to
448 accumulate fat or lost their plasticity and thus be less responsive to geometrical changes.
449 Future work in patients with biopsy-characterised hepatic tissue should help to shed light on
450 the heterogeneity of response to the interaction between liver fat accumulation and liver
451 health status.

452

453 Our analyses allow for the visualisation of significant regional changes across the
454 liver. Of note, we found that diagnosis of liver disease was associated with an inward shape
455 variation at the anterior part of the right lobe, and posterior parts of the left and right lobes
456 accompanied by an outward increase in liver S2S distances in the anterior part of the left
457 lobe. Previous studies have suggested that statistical shape modelling may be used to
458 predict and stage fibrosis based on changes in liver shape [13, 44]. With limited outcome
459 and longitudinal data in the current study, the clinical significance of these changes,
460 particularly the simultaneous regional inward and outward deformations in S2S distances are
461 unclear. However, histological and radiological studies of the liver in patients with cirrhosis
462 have shown that the degree of volume reduction and fibrosis is greater in the right lobe
463 compared to the caudate lobe (which reportedly expands) [45]. This suggests regional
464 changes in S2S distances may reflect physiological processes in the liver. It is well
465 established that many diseases do not progress uniformly across the liver, with differences
466 reported within different zones (periportal, mid-lobular and pericentral) of the liver lobule,
467 which may reflect populations, different cell types, metabolic function and differences in
468 blood flow [46]. Whilst it is premature to adjudicate a mechanism responsible for the
469 changes described in the current study, the regional shape differences associated to both
470 AST:ALT and FIB-4, hinting at hepatocellular changes underpinning the variation in S2S
471 distances.

472

473 Our study was not without limitations. To ensure sufficient numbers of participants in
474 the liver disease group, we included all participants in the imaging cohort who had a

475 diagnosis of liver disease, regardless of aetiology (alcoholic, toxic and inflammatory liver
476 disease, hepatitis, fibrosis and cirrhosis). This precludes us from a more in-depth granular
477 analysis, although our data does suggest that hepatocellular damage, particularly in more
478 advanced disease stages, resulted in significant S2S changes across the liver. Variation in
479 disease aetiology, the point of disease progression and the impact of on-going treatment
480 may further confound the interpretation of our observations in the liver disease cohort.

481

482 **Conclusion**

483

484 This study demonstrates that methods to assess changes in liver morphology,
485 beyond simplistic volumetric analysis, can be applied at scale. In a population-based study
486 we show that inter- and intra-subjects' morphometric variations are associated with age,
487 body composition and liver phenotypes, as well as disease. The approach developed here
488 will allow large-scale studies of patient-based cohorts, enable disease-specific changes in
489 morphology to be defined and tracked during both progression and remission and facilitate
490 disease prediction and stratification.

491

492 **Declarations**

493

494 **Competing interests**

495 M.C. and E.P.S. are employees of Calico Life Sciences LLC. M.T., N.B., B.W., J.D.B. and
496 E.L.T. declare no competing interests.

497

498 **Ethics approval and consent to participate**

499 The data resources used in this study have approval from ethics committees. Full
500 anonymised images and participants metadata from the UK Biobank cohort was
501 obtained through UK Biobank Access Application number 44584. The UK Biobank has
502 approval from the North West Multi-Centre Research Ethics Committee (REC reference:

503 11/NW/0382), and obtained written informed consent from all participants prior to the study.

504 All methods were performed in accordance with the relevant guidelines and regulations as

505 presented by the relevant authorities, including the Declaration of Helsinki

506 <https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics> .

507

508 **Consent for publication**

509 Not applicable.

510

511 **Availability of data and materials**

512 The data that support the findings of this study are available from the UK Biobank

513 (<https://www.ukbiobank.ac.uk>), but restrictions apply to the availability of these data, which

514 were used under license for the current study, and so are not publicly available. Data are

515 however returned by us to the UK Biobank where they will be fully available on request.

516

517 **Funding**

518 This study was funded by Calico Life Sciences LLC.

519

520 **Authors' contributions**

521 J.D.B., E.L.T., M.T. and M.C. conceived the study. J.D.B., B.W., E.L.T., N.B. and M.T.

522 designed the study. M.T., N.B., B.W., E.P.S. and M.C. implemented the methods and

523 performed the data analysis. M.T. defined the disease and physiological condition

524 categories. M.T. performed the image and statistical analysis. E.L.T., B.W., M.T., J.D.B., and

525 N.B. drafted the manuscript. All authors read and approved the manuscript.

526

527 **Acknowledgements**

528 This research has been conducted using the UK Biobank Resource under Application

529 Number 44584.

530

531 **References**

532

533 1. Vos et al. Global burden of 369 diseases and injuries in 204 countries and territories,
534 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*.
535 2020;396:1204–22.

536 2. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al.
537 Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of
538 hepatic steatosis in the general population. *Am J Physiol Endocrinol Metab*. 2005;288:E462–
539 8.

540 3. Wilman HR, Kelly M, Garratt S, Matthews PM, Milanese M, Herlihy A, et al.
541 Characterisation of liver fat in the UK Biobank cohort. *PLoS One*. 2017;12:e0172921.

542 4. Parisinos CA, Wilman HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, et al.
543 Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the
544 pathogenesis of steatohepatitis. *J Hepatol*. 2020;73:241–51.

545 5. Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, et al. Clinical
546 Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic
547 Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-
548 Analysis. *Clinical Gastroenterology and Hepatology*. 2021.

549 6. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic
550 Resonance Elastography vs Transient Elastography in Detection of Fibrosis and
551 Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty
552 Liver Disease. *Gastroenterology*. 2017;152:598–607.e2.

553 7. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in
554 Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-

- 555 analysis of Paired-Biopsy Studies. *Clinical Gastroenterology and Hepatology*. 2015;13:643–
556 54.e9.
- 557 8. Asaturyan H, Thomas EL, Bell JD, Villarini B. A Framework for Automatic Morphological
558 Feature Extraction and Analysis of Abdominal Organs in MRI Volumes. *J Med Syst*.
559 2019;43:334.
- 560 9. Liu Y, Bastý N, Whitcher B, Bell JD, Sorokin EP, van Bruggen N, et al. Genetic
561 architecture of 11 organ traits derived from abdominal MRI using deep learning. *Elife*.
562 2021;10.
- 563 10. Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE. *Statistical Parametric
564 Mapping: The Analysis of Functional Brain Images*. Elsevier; 2011.
- 565 11. Ramezani M, Johnsrude I, Rasoulían A, Bosma R, Tong R, Hollenstein T, et al.
566 Temporal-lobe morphology differs between healthy adolescents and those with early-onset
567 of depression. *NeuroImage: Clinical*. 2014;6:145–55.
- 568 12. Nakao M, Nakamura M, Mizowaki T, Matsuda T. Statistical deformation reconstruction
569 using multi-organ shape features for pancreatic cancer localization. *Med Image Anal*.
570 2021;67:101829.
- 571 13. Hori M, Okada T, Higashiura K, Sato Y, Chen Y-W, Kim T, et al. *Quantitative Imaging*.
572 *Academic Radiology*. 2015;22:303–9.
- 573 14. Biffi C, de Marvao A, Attard MI, Dawes TJW, Whiffin N, Bai W, et al. Three-dimensional
574 cardiovascular imaging-genetics: a mass univariate framework. *Bioinformatics*. 2018;34:97–
575 103.
- 576 15. Jia S, Nivet H, Harrison J, Pennec X, Camaioni C, Jaïs P, et al. Left atrial shape is
577 independent predictor of arrhythmia recurrence after catheter ablation for atrial fibrillation: A
578 shape statistics study. *Heart Rhythm O2*. 2021;2 6Part A:622–32.

- 579 16. Marvao A de, de Marvao A, McGurk KA, Zheng SL, Thanaj M, Bai W, et al. Phenotypic
580 Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic
581 Cardiomyopathy. *Journal of the American College of Cardiology*. 2021;78:1097–110.
- 582 17. Smith SM, Elliott LT, Alfaro-Almagro F, McCarthy P, Nichols TE, Douaud G, et al. Brain
583 aging comprises many modes of structural and functional change with distinct genetic and
584 biophysical associations. *Elife*. 2020;9.
- 585 18. Wang X, Vrtiska TJ, Avula RT, Walters LR, Chakkera HA, Kremers WK, et al. Age,
586 kidney function, and risk factors associate differently with cortical and medullary volumes of
587 the kidney. *Kidney Int*. 2014;85:677–85.
- 588 19. Fitzpatrick JA, Kim JU, Cobbold JFL, McPhail MJW, Crossey MME, Bak-Bol AA, et al.
589 Changes in Liver Volume in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy.
590 *J Clin Exp Hepatol*. 2016;6:15–20.
- 591 20. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
592 access resource for identifying the causes of a wide range of complex diseases of middle
593 and old age. *PLoS Med*. 2015;12:e1001779.
- 594 21. Littlejohns TJ, Holliday J, Gibson LM, Garratt S, Oesingmann N, Alfaro-Almagro F, et al.
595 The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection,
596 management and future directions. *Nature Communications*. 2020;11.
- 597 22. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. *Am Fam Physician*.
598 2006;73:1961–8.
- 599 23. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. *BMJ*. 2014;349:g4596.
- 600 24. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development
601 of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV
602 coinfection. *Hepatology*. 2006;43:1317–25.

- 603 25. Yang G, Zhou S, Bozek J, Dong H-M, Han M, Zuo X-N, et al. Sample sizes and
604 population differences in brain template construction. *Neuroimage*. 2020;206:116318.
- 605 26. Whitcher B, Thanaj M, Cule M, Liu Y, Basty N, Sorokin EP, et al. Precision MRI
606 phenotyping enables detection of small changes in body composition for longitudinal
607 cohorts. *Sci Rep*. 2022;12:3748.
- 608 27. Thanaj M, Basty N, Liu Y, Cule M, Sorokin EP, Louise Thomas E, et al. Mass Univariate
609 Regression Analysis for Three-Dimensional Liver Image-Derived Phenotypes. *Medical
610 Image Understanding and Analysis*. 2021;:165–76.
- 611 28. Bai W, Shi W, de Marvao A, Dawes TJW, O'Regan DP, Cook SA, et al. A bi-ventricular
612 cardiac atlas built from 1000 high resolution MR images of healthy subjects and an analysis
613 of shape and motion. *Medical Image Analysis*. 2015;26:133–45.
- 614 29. Duan J, Bello G, Schlemper J, Bai W, Dawes TJW, Biffi C, et al. Automatic 3D Bi-
615 Ventricular Segmentation of Cardiac Images by a Shape-Refined Multi- Task Deep Learning
616 Approach. *IEEE Trans Med Imaging*. 2019;38:2151–64.
- 617 30. Smith S, Nichols T. Threshold-free cluster enhancement: Addressing problems of
618 smoothing, threshold dependence and localisation in cluster inference. *NeuroImage*.
619 2009;44:83–98.
- 620 31. Biffi et al. 2017. Biffi C. An introduction to mass univariate analysis of three-dimensional
621 phenotypes, <https://github.com/UK-Digital-Heart-Project/mutools3D>, R package version 1.0
622 (2017).
- 623 32. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
624 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B
625 (Methodological)*. 1995;57:289–300.
- 626 33. DeLand FH, North WA. Relationship between liver size and body size. *Radiology*.

- 627 1968;91:1195–8.
- 628 34. Heymsfield SB, Olafson RP, Kutner MH, Nixon DW. A radiographic method of
629 quantifying protein-calorie undernutrition. *The American Journal of Clinical Nutrition*.
630 1979;32:693–702.
- 631 35. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of
632 age upon liver volume and apparent liver blood flow in healthy man. *Hepatology*.
633 1989;9:297–301.
- 634 36. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume
635 from birth to adulthood: a meta-analysis. *Liver Transpl*. 2005;11:1481–93.
- 636 37. Yanaga K, Honda H, Ikeda Y, Nishizaki AT, Yamamoto K, Sugimachi K. Significance of
637 Liver Size in Hepatic Surgery. *HPB Surgery*. 1997;10:195–200.
- 638 38. Kratzer W, Fritz V, Mason RA, Haenle MM, Kaechele V, Roemerstein Study Group.
639 Factors Affecting Liver Size. *Journal of Ultrasound in Medicine*. 2003;22:1155–61.
- 640 39. Patzak M, Porzner M, Oeztuerk S, Mason RA, Wilhelm M, Graeter T, et al. Assessment
641 of liver size by ultrasonography. *J Clin Ultrasound*. 2014;42:399–404.
- 642 40. Kromrey ML, Ittermann T, vWahsen C, Plodeck V, Seppelt D, Hoffmann RT, et al.
643 Reference values of liver volume in Caucasian population and factors influencing liver size.
644 *Eur J Radiol*. 2018;106:32–7.
- 645 41. Marchesini G, Bua V, Brunori A, Bianchi G, Pisi P, Fabbri A, et al. Galactose elimination
646 capacity and liver volume in aging man. *Hepatology*. 1988;8:1079–83.
- 647 42. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global
648 epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and
649 meta-analysis. *J Hepatol*. 2019;71:793–801.

- 650 43. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The
651 economic and clinical burden of nonalcoholic fatty liver disease in the United States and
652 Europe. *Hepatology*. 2016;64:1577–86.
- 653 44. Soufi M, Otake Y, Hori M, Moriguchi K, Imai Y, Sawai Y, et al. Liver shape analysis using
654 partial least squares regression-based statistical shape model: application for understanding
655 and staging of liver fibrosis. *Int J Comput Assist Radiol Surg*. 2019;14:2083–93.
- 656 45. Harbin WP, Robert NJ, Ferrucci JT Jr. Diagnosis of cirrhosis based on regional changes
657 in hepatic morphology: a radiological and pathological analysis. *Radiology*. 1980;135:273–
658 83.
- 659 46. Cunningham RP, Porat-Shliom N. Liver Zonation – Revisiting Old Questions With New
660 Technologies. *Frontiers in Physiology*. 2021;12.